Found 6,914 clinical trials
TMS in Anxiety-Parkinson's Disease
Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's dementia. Anxiety in PD is common, has major effects on quality of life and contributes to increased disability. The reported prevalence of anxiety in PD ranges widely and is estimated up to 40%. Treatment with oral medications is …
Testing the Safety and Exploring the Biomarker Effects of Oral Liquid Low-dose Carbon Monoxide in People with Parkinson's
This study is testing the safety and short-term effects of HBI-002 in people with Parkinson's. There is evidence that low blood levels of carbon monoxide produced by smoking cigarettes may help explain why smokers are less likely to get Parkinson's, and may benefit people with Parkinson's without subjecting them to …
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combination with …
Effect of EMDR for Reduction of Pain Interference in Children With Sickle Cell Disease
Children with sickle cell disease may experience frequent painful episodes. This, together with the traumatic experiences during a hospitalization, can lead to the development of posttraumatic stress reactions. As the stress can trigger painful episodes (pain crisis) in children with sickle cell disease, the investigators think that treating these stress …
Visual Performance of Clareon PanOptix vs. a Comparable Multifocal Intraocular Lens
This is a two-part, multi-center, investigator-initiated clinical study comparing visual outcomes and patient satisfaction in subjects receiving bilateral implantation of either the Clareon PanOptix intraocular lens (IOL) or a comparable multifocal IOL. The study includes a retrospective/prospective pilot phase and a prospective, randomized comparison phase.
Exploring Barriers and Facilitators to Social Participation
This study aims to explore the barriers and facilitators to social participation for individuals living with progressive neurological conditions in Wales. Please click here to take part in the study: https://cardiff.qualtrics.com/jfe/form/SV_4GRdoCPu6ELiUnA
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
The study aims to evaluate the burden of tau pathology in people with Sporadic and LRRK2 PD via in vivo imaging using the tau tracer, [18F]PI-2620, and a high resolution PET camera, NeuroEXPLORER.
Intrapatient Comparison of STN and GPi tTIS in PD
The goal of this clinical trial is to investigate the therapeutic efficacy of tTIS in patients with Parkinson's disease and to evaluate the immediate effects and conduct intrapatient comparisons of individualized 130 Hz Subthalamic Nucleus-transcranial Temporal Interference Stimulation (STN-tTIS) and Globus Pallidus Internus-transcranial Temporal Interference Stimulation (GPi-tTIS) on motor symptoms …
Integrating AI in Postural Rehabilitation for Parkinson's Disease
Postural abnormalities are highly disabling complications of Parkinson's disease (PD). These include camptocormia, anterocollis, and Pisa Syndrome (PS). PS is characterized by a lateral trunk flexion (LTF) typically exceeding 10 degrees, often accompanied by axial rotation, asymmetric shoulder positioning, and poor awareness of the postural alteration. This condition worsens during …
A Phase 1/2a Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
